| abstract |
The present disclosure provides methods for treating hematological malignancies (e.g., AML) using an effective amount of an anti-CD200 antibody, or antigen-binding fragment thereof, an anti-metabolic agent (e.g., cytarabine), and a topoisomerase inhibitor (e.g., daunorubicin). |